Polio vaccine

Medicine helps kids stay safe.

One medicine stops a bad sickness called polio.

There are two ways to take it. One way is a shot.

The other way is a drink. Some people even take it on a sugar cube.

These medicines work well. They have helped stop polio in most of the world.

In 1988, many people were sick. By 2018, only a few people were sick.

Doctors want all children to get these medicines. They help keep everyone healthy.

Polio is a sickness that can make people very ill.

A vaccine is a way to stop this sickness. There are two main types of vaccines.

The first type is the IPV. This is a shot given by an injection. It uses an inactivated virus, which means the virus is killed. The IPV is very safe. It helps the body make antibodies. Antibodies are parts of the body that fight germs.

The second type is the OPV. This is an oral vaccine. It is given by mouth. This vaccine uses a weakened virus. It is easy to give to many people at once. It does not need needles.

These vaccines have changed the world. In 1988, about 350,000 people had polio. By 2018, only 33 cases were reported. The WHO, a group that studies health, says all children should get these vaccines. New vaccines are being made to keep people even safer.

A polio vaccine is a way to stop a sickness called poliomyelitis. This disease can be very serious for people. Scientists use vaccines to teach the body how to fight the virus. There are two main kinds of vaccines used today.

One is the inactivated poliovirus vaccine, or IPV. This is given as a shot through an injection. The other is the oral poliovirus vaccine, or OPV. This version is given by mouth.

The IPV works by using a killed version of the virus. When a person gets the shot, their body develops protective antibodies. These antibodies help the body recognize and fight the virus later. After three doses, at least 99% of people are immune.

The OPV works a bit differently because it uses a weakened virus. This version is easy to give to large groups of people. It does not need needles or special medical equipment. It also creates immunity in the intestines where the virus usually enters.

Many scientists worked hard to create these tools. Hilary Koprowski showed the first success in 1950. He used a live virus that people drank. Jonas Salk later developed the killed vaccine. He announced his success in 1955.

Albert Sabin developed another oral vaccine. This one became used by many people in 1961. These discoveries changed how we protect children everywhere.

These vaccines have helped reduce polio cases a lot. In 1988, there were about 350,000 cases every year. By 2018, that number dropped to only 33 cases.

However, the oral vaccine has a very small risk. It can sometimes cause vaccine-associated paralytic poliomyelitis, or VAPP. This happens in about one person for every 2.7 million doses. Scientists are now making a new vaccine called nOPV2. This new version is more stable and safer.

Vaccines are part of how we keep the whole world healthy. The World Health Organization, or WHO, says all children should be vaccinated. They keep a list of essential medicines that everyone needs.

Using vaccines helps stop the virus from moving from person to person. This is how we can eventually stop polio for good. It is a big job that scientists and doctors work on every day.

A polio vaccine is a medical tool used to prevent poliomyelitis, commonly known as polio. This disease is caused by a virus that can lead to serious health issues. Vaccines work by training the human immune system to recognize and fight the virus. There are two primary types of vaccines used in global health efforts today. One is the inactivated poliovirus vaccine, or IPV, which is administered via injection. The other is the oral poliovirus vaccine, or OPV, which is given by mouth.

Both types are essential tools for the World Health Organization (WHO) in its goal to eradicate the disease.

The IPV works by using a killed version of the virus. This version is grown in a type of monkey kidney tissue culture called a Vero cell line. Scientists then use formalin to inactivate the virus so it cannot cause disease. When a person receives the injection, their body develops IgG-mediated immunity in the bloodstream. This prevents the virus from progressing to the nervous system. After two doses, 90% or more of people develop protective antibodies to all three poliovirus serotypes. Following three doses, at least 99% of recipients are immune.

The OPV works differently because it uses a live-attenuated virus. This means the virus is alive but has been weakened so it does not cause serious illness. Because it is given by mouth, it is very easy to administer during mass vaccination campaigns. It does not require sterile syringes or extensive medical training. OPV is particularly effective because it creates immunity in the intestines. This is the primary site where the wild poliovirus enters the body. One dose of trivalent OPV produces immunity in about 50% of recipients. Three doses can produce protective antibodies in more than 95% of people.

History shows a progression of different vaccine technologies. In 1950, Hilary Koprowski demonstrated the first successful polio vaccine. He used a live attenuated virus that people drank. While it was not approved in the United States, it was used successfully in other places. In 1955, Jonas Salk announced the success of his inactivated vaccine. Later, in 1961, Albert Sabin’s live oral vaccine came into commercial use.

These different approaches provided scientists with various ways to fight the virus globally.

The impact of these vaccines on global health is massive. In 1988, there were an estimated 350,000 reported cases of polio each year. By 2018, that number had dropped to just 33 cases.

This reduction is due to the interruption of person-to-person transmission. Poliovirus has no non-primate reservoir in nature, meaning it only lives in humans. Additionally, there is no long-term carrier state for the virus in people with normal immune function. This makes it possible to stop the virus entirely through high vaccination coverage.

However, the OPV carries a small, inherent risk. Because it uses a live virus, it can cause vaccine-associated paralytic poliomyelitis, or VAPP. This occurs in roughly one individual per every 2.7 million doses. In under-vaccinated populations, the vaccine virus can circulate and revert to a neurovirulent form. This is called circulating vaccine-derived poliovirus, or cVDPV. In 2017, cVDPV cases actually outnumbered wild polio cases for the first time.

To solve this, scientists developed the novel oral polio vaccine type 2, or nOPV2. This new vaccine is genetically modified to be more stable and less likely to cause outbreaks.

Vaccination schedules vary depending on the risk of polio in a specific country. In areas where polio is still present, the WHO recommends a mix of OPV and IPV. This often starts with OPV at birth, followed by a primary series of three OPV doses. In countries with very high immunization coverage, the focus shifts more toward IPV. For the highest-risk areas, a primary series of three IPV injections is recommended.

These complex schedules ensure that different populations receive the specific protection they need to stay safe.